SecurityGEC / Great Elm Capital Group, Inc. (39036P100)
Institutional Owners47 (8 N-Q Owners)
Institutional Shares12,187,477 - 0.05% (ex. N-Q)
Common Stock Shares Outstanding24,706,115,000 shares (as of 2018-03-31)
Institutional Value$ 51,368,000 USD (ex. N-Q)

Institutional Stock Ownership and Shareholders

GEC / Great Elm Capital Group, Inc.  Institutional Ownership

Great Elm Capital Group, Inc. (NASDAQ:GEC) has 47 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 12,187,477 shares. Largest shareholders include Northern Right Capital Management, L.P., Cove Street Capital, LLC, Kingdon Capital Management, L.l.c., Arbiter Partners Capital Management LLC, Renaissance Technologies LLC, Glacier Peak Capital LLC, Vanguard Group Inc, Royce & Associates LLC, Russell Investments Group, Ltd., and Roumell Asset Management, LLC.
Great Elm Capital Group, Inc. (NASDAQ:GEC) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/gec"><img src="https://images.fintel.io/us-gec-so.png" alt="GEC / Great Elm Capital Group, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-03-01 N-Q Investment Managers Series Trust Ii (see advisory)
2018-05-14 13F-HR CANNELL CAPITAL LLC 259,299 259,299 0.00 1,050 1,037 -1.24
2018-02-23 N-Q Managed Portfolio Series (see advisory)
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 120,848 120,123 -0.60 489 480 -1.84
2018-02-28 N-Q Relative Value Fund (see advisory)
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 50,981 68,599 34.56 206 274 33.01
2018-05-15 13F-HR BARCLAYS PLC 1 0
2018-05-11 13F-HR Cove Street Capital, LLC 1,992,783 1,972,483 -1.02 8,070 7,890 -2.23
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 69,202 61,717 -10.82 280 247 -11.79
2018-05-15 13F-HR Glacier Peak Capital LLC 801,674 3,207
2018-05-15 13F-HR KINGDON CAPITAL MANAGEMENT, L.L.C. 1,267,030 1,267,030 0.00 5,131 5,068 -1.23
2018-05-01 13F-HR OPPENHEIMER & CO INC 53,293 53,293 0.00 216 213 -1.39
2018-01-16 13F-HR NEXT Financial Group, Inc 54 0 -100.00 0 0
2018-04-30 13F-HR Monarch Partners Asset Management LLC 85,490 133,200 55.81 346 533 54.05
2018-02-28 N-Q Gator Series Trust (see advisory)
2018-05-09 13F-HR NORTHERN TRUST CORP 33,937 35,408 4.33 137 142 3.65
2018-05-15 13F-HR OXFORD ASSET MANAGEMENT 23,814 14,914 -37.37 94 60 -36.17
2018-04-20 13F-HR Seacrest Wealth Management, Llc 12 12 0.00 0 0
2018-05-10 13F-HR Gator Capital Management, LLC 77,697 77,697 0.00 315 311 -1.27
2018-04-05 13F-HR Destination Wealth Management 155,233 3,207
2018-04-16 13F-HR Westside Investment Management, Inc. 8 8 0.00 29 31 6.90
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 12 0 -100.00 0 0
2018-05-14 13F-HR MORGAN STANLEY 1 1 0.00 0 0
2018-05-15 13F-HR Northern Right Capital Management, L.P. 2,402,792 2,402,792 0.00 9,731 9,611 -1.23
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 2 2 0.00 0 0
2018-05-15 13F-HR DEUTSCHE BANK AG\ 63,910 42,638 -33.28 258 170 -34.11
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 168 168 0.00 1 1 0.00
2018-05-07 13F-HR SYNOVUS FINANCIAL CORP 0 2 0 0
2018-05-11 13F-HR Russell Investments Group, Ltd. 489,999 489,999 0.00 1,936 1,960 1.24
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 1,375 1,376 0.07 6 6 0.00
2018-05-15 13F-HR Advisor Group, Inc. 0 210 0 1
2018-01-26 N-Q Fidelity Concord Street Trust (see advisory)
2018-02-28 N-Q Vivaldi Opportunities Fund (see advisory)
2018-05-08 13F-HR Vivaldi Asset Management, LLC 27,144 0 -100.00 110 0 -100.00
2018-02-09 13F-HR Tower Research Capital LLC (TRC) 349 0 -100.00 1 0 -100.00
2018-05-04 13F-HR Opus Capital Group, LLC 25,000 35,000 40.00 101 140 38.61
2018-05-14 13F-HR Royce & Associates LLC 540,745 570,745 5.55 2,190 2,283 4.25
2018-01-29 N-Q Starboard Investment Trust (see advisory)
2018-05-14 13F-HR Renaissance Technologies LLC 959,509 920,109 -4.11 3,886 3,680 -5.30
2018-02-28 N-Q Ishares Trust (see advisory)
2018-05-15 13F-HR Arbiter Partners Capital Management LLC 1,150,000 1,150,000 0.00 4,658 4,600 -1.25
2018-05-17 13F-HR Nvwm, Llc 2 2 0.00 0 0
2018-05-23 13F-HR EQUITEC PROPRIETARY MARKETS, LLC 25,300 25,300 0.00 102 101 -0.98
2018-05-15 13F-HR Bank of New York Mellon Corp 37,403 40,523 8.34 151 162 7.28
2018-05-14 13F-HR Roumell Asset Management, LLC 363,799 363,799 0.00 1,473 1,455 -1.22
2018-05-15 13F-HR STATE STREET CORP 11,092 11,092 0.00 45 45 0.00
2018-05-15 13F-HR VANGUARD GROUP INC 722,679 723,819 0.16 2,927 2,896 -1.06
2018-05-15 13F-HR UBS Group AG 179 438 144.69 1 2 100.00
2018-05-09 13F-HR BlackRock Inc. 321,702 317,105 -1.43 1,304 1,269 -2.68
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 47,867 47,867 0.00 194 191 -1.55
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 23,799 95
2018-05-10 13F-HR JP Morgan Chase & Co 3,313 0 -100.00 13 0 -100.00

Form N-Q Advisory - Experimental Feature Here!

We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.

However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.

Limitations:

  • We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( GEC / Great Elm Capital Group, Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
  • We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.

These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Great Elm Capital Group, Inc. 2018 Q3 - Results - Earnings Call Slides

2018-05-17 seekingalpha
The following slide deck was published by Great Elm Capital Group, Inc. in conjunction with their 2018 Q3 earnings call.

Qualcomm's Biggest Risk Is A Negative FTC Outcome

2018-04-02 seekingalpha
Qualcomm (QCOM) has been fighting a war on multiple fronts that has taken a toll on its stock. While on the face it the stock seems cheap, there are many issues that are not clear with the naked eye that might drag shares lower. (174-0)

BRIEF-Great Elm Capital Group Says Richard Chernicoff Resigned As COO, Member Of Board

2018-03-23 reuters
* GREAT ELM CAPITAL GROUP SAYS ON MARCH 21, RICHARD CHERNICOFF RESIGNED AS CHIEF OPERATING OFFICER AND MEMBER OF BOARD - SEC FILING

Great Elm (GEC) To Make Real Estate Investment Through Acquisition in Fort Myers - Slideshoe

2018-03-08 seekingalpha
The following slide deck was published by Great Elm Capital Group, Inc. in conjunction with this event.

BRIEF-Great Elm Capital Group Reports Q2 2018 Financial Results

2018-03-07 reuters
* GREAT ELM CAPITAL GROUP, INC. REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS, INVESTMENT IN COMMERCIAL REAL ESTATE UNDER LONG-TERM LEASE TO CREDIT-WORTHY TENANT AND NEW INVESTMENT MANAGEMENT AGREEMENTS

CUSIP: 39036P100